Citius Oncology, Inc.

About Citius Oncology, Inc.

Citius Oncology, Inc. (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. Their mission includes advancing treatments like LYMPHIR™, an FDA-approved targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). It is a majority-owned publicly-traded subsidiary of Citius Pharmaceuticals, Inc.

Products & Services

LYMPHIR™ (denileukin diftitox-cxdl):A targeted immune therapy approved by the FDA in August 2024 for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

IL-2R Targeted Immunotherapy:A treatment targeting IL-2R, described as a logical approach for CTCL therapy.

Combination Therapy:Two investigator-initiated trials are underway to explore combination therapy potential.

LYMPHIR™ (denileukin diftitox-cxdl)

Specialties

Targeted Oncology Therapies Immunotherapy Cutaneous T-cell Lymphoma (CTCL) Treatments Targeted oncology therapies Immune therapy for CTCL

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 18000000 MR: - FA: approximately $18 million FAN: 18000000	D: 2025-12-10 FD: 2025-12-10	1 investors
2	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 18000000 MR: - FA: approximately $18 million FAN: 18000000	D: 2025-12-09 FD: 2025-12-09	1 investors
3	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 9000000 MR: - FA: 9.0 million FAN: 9000000	D: 2025-09-10 FD: 2025-09-10	1 investors
4	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 9000000 MR: - FA: 9.0 Million FAN: 9000000	D: 2025-09-09 FD: 2025-09-09	1 investors
5	RT: Public Offering T: - FT: Public Offering	A: 9000000 MR: - FA: $9.0 Million FAN: 9000000	D: 2025-07-17 FD: 2025-07-17	1 investors
6	RT: Public Offering T: - FT: Public Offering	A: 9000000 MR: - FA: 9.0 million FAN: 9000000	D: 2025-07-16 FD: 2025-07-16	1 investors

Registered Direct Offering and Private Placement Latest

2025-12-10

$18.0M

1 investor (Pro only)

Registered Direct Offering and Private Placement 2025-12-09

$18.0M

Registered Direct Offering and Concurrent Private Placement 2025-09-10

$9.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Leonard Mazur

Chief Executive Officer and President

M

Myron Holubiak

Secretary, Board of Directors

J

Jaime Bartushak

Chief Financial Officer and Treasurer

M

Myron Czuczman

Chief Medical Officer

L

Leonard Mazur

Chairman

M

Myron Holubiak

Secretary

View 9 more team members with Pro

Unlock Full Team Directory

Recent News